RVPH

Reviva Pharmaceuticals Holdings, Inc.

Add to Watchlist

Advanced Chart

0.790

-0.044(-5.270%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

0.858

Open

0.839

VWAP

0.82

Vol

331.98K

Mkt Cap

36.92M

Low

0.790

Amount

271.76K

EV/EBITDA(TTM)

Total Shares

29.82M

25.98M

EV/OCF(TTM)

P/S(TTM)

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

5 Analyst Rating

1324.05% Upside

Wall Street analysts forecast RVPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVPH is 11.25 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

1324.05% Upside

Current: 0.790

Low

7.00

Averages

11.25

High

16.00

1324.05% Upside

Current: 0.790

Low

7.00

Averages

11.25

High

16.00

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-04-24

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-04-24

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$15 → $8

2025-04-01

Reason

D. Boral Capital

Jason Kolbert

Price Target

$15 → $8

2025-04-01

Maintains

Strong Buy

Reason

D. Boral Capital analyst Jason Kolbert lowered the firm's price target on Reviva Pharmaceuticals to $8 from $15 and keeps a Buy rating on the shares following the Q4 report. The firm cites the "depressed valuation" of the stock and the company's need for capital for the target cut. However, it still believes in the therapeutic potential of brilaroxazine.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$14 → $11

2025-01-22

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$14 → $11

2025-01-22

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$15

2025-01-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

$15

2025-01-21

Maintains

Strong Buy

Reason

Roth MKM

Boobalan Pachaiyappan

Strong Buy

Initiates

2025-01-10

Reason

Roth MKM

Boobalan Pachaiyappan

Price Target

2025-01-10

Initiates

Strong Buy

Reason

Roth MKM initiated coverage of Reviva Pharmaceuticals with a Buy rating and $7 price target. The firm says its optimism is driven by brilaroxazine's positive Phase 3 data demonstrating its impact on positive, negative and cognition symptoms in schizophrenia patients with an effect size greater than many antipsychotics. The "unequivocal" Phase 3 results underscore Reviva's "de-risked clinical strategy," the analyst tells investors in a research note.

Maxim Group

Jason McCarthy

Hold

Strong Buy

Upgrades

2025-01-10

Reason

Maxim Group

Jason McCarthy

Price Target

2025-01-10

Upgrades

Hold

Strong Buy

Reason

Maxim analyst Jason McCarthy upgraded Reviva Pharmaceuticals to Buy from Hold with a $7 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Reviva Pharmaceuticals Holdings, Inc. (RVPH.O) is -1.18, compared to its 5-year average forward P/E of -7.15. For a more detailed relative valuation and DCF analysis to assess Reviva Pharmaceuticals Holdings, Inc. 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.15

Current PE

-1.18

Overvalued PE

6.40

Undervalued PE

-20.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2024Q4

N/A

Total Revenue

FY2024Q4

YoY :

-37.08%

-6.28M

Operating Profit

FY2024Q4

YoY :

-35.63%

-6.26M

Net Income after Tax

FY2024Q4

YoY :

-55.56%

-0.16

EPS - Diluted

FY2024Q4

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RVPH News & Events

Events Timeline

2024-12-17 (ET)

2024-12-17

05:40:35

Reviva Pharmaceuticals 12M share Spot Secondary priced at $1.50

2024-12-16 (ET)

2024-12-16

16:20:06

Reviva Pharmaceuticals announces common stock, warrant offering, no amount given

2024-11-14 (ET)

2024-11-14

16:26:10

Reviva Pharmaceuticals reports Q3 EPS (25c), consensus (25c)

News

1.0

04-24Newsfilter

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

6.0

04-01Benzinga

Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday

9.5

03-31Newsfilter

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights